deferoxamine has been researched along with Parkinson Disease in 24 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Herein, we discuss the various dosing regimens and formulations employed in intranasal (IN) or systemic DFO treatment, as well as the physiological and behavioral outcomes observed in animal models of AD, PD, and ICH." | 6.72 | Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage. ( Farr, AC; Xiong, MP, 2021) |
| " In this study, we have conjugated DFOB to derivatives of adamantane or the clinical iron chelator deferasirox to produce lipophilic compounds designed to increase the bioavailability of DFOB to brain cells." | 5.39 | Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease. ( Codd, R; Crouch, PJ; Ganio, G; Liddell, JR; Liu, J; Mok, SS; Obando, D; Volitakis, I; White, AR, 2013) |
| " Herein, we discuss the various dosing regimens and formulations employed in intranasal (IN) or systemic DFO treatment, as well as the physiological and behavioral outcomes observed in animal models of AD, PD, and ICH." | 2.72 | Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage. ( Farr, AC; Xiong, MP, 2021) |
| " Factors such as brain penetrance and bioavailability have limited the advancement of potential antioxidant and iron chelator therapies for PD." | 1.56 | Deferoxamine and Curcumin Loaded Nanocarriers Protect Against Rotenone-Induced Neurotoxicity. ( Mursaleen, L; Somavarapu, S; Zariwala, MG, 2020) |
| "The reversal of catalepsy behaviour represents the protective effect of above combination on dopamine neurons in striatum from 6-OHDA toxicity." | 1.51 | Desferrioxamine and dextromethorphan combination exhibited synergistic effect and reversed the catalepsy behaviour in 6-hydroxydopamine hydroydopamine administered rats through regulating brain glutamate levels. ( Antony, J; Choephel, T; Jeyarani, V; Jose, A; Kannan, E; Karolina Sahadevan, S; Manisha, C; Mannan Thodukayil, N; Thomas, P, 2019) |
| "Parkinson disease is a neurodegenerative disorder of aging, characterized by disabling motor symptoms resulting from the loss of midbrain dopaminergic neurons and the decrease of dopamine in the striatum." | 1.42 | Neuroprotective effects of a brain permeant 6-aminoquinoxaline derivative in cell culture conditions that model the loss of dopaminergic neurons in Parkinson disease. ( Amar, M; Brunelle, A; Debortoli, L; Ferrié, L; Figadère, B; Kadar, H; Latini, A; Le Douaron, G; Michel, PP; Raisman-Vozari, R; Schmidt, F; Séon-Méniel, B; Touboul, D, 2015) |
| "Rat models with 6-OHDA-induced Parkinson's disease were treated with curcumin, DFO, or both and the effect of different treatments on dopamine level was examined." | 1.40 | Ameliorating effects of combined curcumin and desferrioxamine on 6-OHDA-induced rat mode of Parkinson's disease. ( Cui, X; Jiang, F; Li, Z; Liu, J; Lv, H; Niu, Y; Wang, L; Wang, W; Yu, S; Yuan, J; Zhang, H, 2014) |
| " Our data suggest that chronic administration of intranasal deferoxamine may be a valid approach to limiting the mishandling of α-synuclein in the central nervous system observed in Parkinson's disease and slowing disease progression." | 1.39 | Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model. ( Andersen, KJ; Febbraro, F; Romero-Ramos, M; Sanchez-Guajardo, V; Tentillier, N, 2013) |
| " In this study, we have conjugated DFOB to derivatives of adamantane or the clinical iron chelator deferasirox to produce lipophilic compounds designed to increase the bioavailability of DFOB to brain cells." | 1.39 | Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease. ( Codd, R; Crouch, PJ; Ganio, G; Liddell, JR; Liu, J; Mok, SS; Obando, D; Volitakis, I; White, AR, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.17) | 18.7374 |
| 1990's | 5 (20.83) | 18.2507 |
| 2000's | 3 (12.50) | 29.6817 |
| 2010's | 12 (50.00) | 24.3611 |
| 2020's | 3 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Le Douaron, G | 2 |
| Schmidt, F | 1 |
| Amar, M | 2 |
| Kadar, H | 1 |
| Debortoli, L | 1 |
| Latini, A | 1 |
| Séon-Méniel, B | 2 |
| Ferrié, L | 2 |
| Michel, PP | 2 |
| Touboul, D | 1 |
| Brunelle, A | 1 |
| Raisman-Vozari, R | 2 |
| Figadère, B | 2 |
| Sepulveda-Diaz, JE | 1 |
| Harfouche, A | 1 |
| Telfer, TJ | 2 |
| Liddell, JR | 2 |
| Duncan, C | 1 |
| White, AR | 2 |
| Codd, R | 3 |
| Cui, J | 1 |
| Yuan, Y | 1 |
| Wang, J | 2 |
| Song, N | 1 |
| Xie, J | 1 |
| Mursaleen, L | 1 |
| Somavarapu, S | 1 |
| Zariwala, MG | 1 |
| Farr, AC | 1 |
| Xiong, MP | 1 |
| Gotsbacher, MP | 1 |
| Witting, PK | 1 |
| Double, KL | 1 |
| Finkelstein, DI | 1 |
| You, L | 1 |
| Liu, T | 1 |
| Zhang, Y | 1 |
| Han, X | 1 |
| Wang, T | 1 |
| Guo, S | 1 |
| Dong, T | 1 |
| Xu, J | 1 |
| Anderson, GJ | 1 |
| Liu, Q | 1 |
| Chang, YZ | 1 |
| Lou, X | 1 |
| Nie, G | 1 |
| Mannan Thodukayil, N | 1 |
| Antony, J | 1 |
| Thomas, P | 1 |
| Jeyarani, V | 1 |
| Choephel, T | 1 |
| Manisha, C | 1 |
| Jose, A | 1 |
| Karolina Sahadevan, S | 1 |
| Kannan, E | 1 |
| Febbraro, F | 2 |
| Andersen, KJ | 1 |
| Sanchez-Guajardo, V | 1 |
| Tentillier, N | 1 |
| Romero-Ramos, M | 2 |
| Lv, H | 1 |
| Liu, J | 2 |
| Wang, L | 1 |
| Zhang, H | 1 |
| Yu, S | 1 |
| Li, Z | 1 |
| Jiang, F | 1 |
| Niu, Y | 1 |
| Yuan, J | 1 |
| Cui, X | 1 |
| Wang, W | 1 |
| Caruana, M | 1 |
| Högen, T | 1 |
| Levin, J | 1 |
| Hillmer, A | 1 |
| Giese, A | 1 |
| Vassallo, N | 1 |
| Giorgi, M | 1 |
| Caldarola, S | 1 |
| Loreni, F | 1 |
| Haleagrahara, N | 1 |
| Siew, CJ | 1 |
| Ponnusamy, K | 1 |
| Obando, D | 1 |
| Ganio, G | 1 |
| Volitakis, I | 1 |
| Mok, SS | 1 |
| Crouch, PJ | 1 |
| Kalivendi, SV | 1 |
| Kotamraju, S | 1 |
| Cunningham, S | 1 |
| Shang, T | 1 |
| Hillard, CJ | 1 |
| Kalyanaraman, B | 1 |
| Youdim, MB | 2 |
| Stephenson, G | 1 |
| Ben Shachar, D | 1 |
| Kooncumchoo, P | 1 |
| Sharma, S | 1 |
| Porter, J | 1 |
| Govitrapong, P | 1 |
| Ebadi, M | 1 |
| Cabrera-Valdivia, F | 1 |
| Jiménez-Jiménez, FJ | 1 |
| Molina, JA | 1 |
| Férnandez-Calle, P | 1 |
| Vázquez, A | 1 |
| Cañizares-Liébana, F | 1 |
| Larumbe-Lobalde, S | 1 |
| Ayuso-Peralta, L | 1 |
| Rabasa, M | 1 |
| Codoceo, R | 1 |
| Ben-Shachar, D | 1 |
| Eshel, G | 1 |
| Finberg, JP | 1 |
| Riederer, P | 2 |
| Kondo, T | 1 |
| Berg, D | 1 |
| Grote, C | 1 |
| Rausch, WD | 1 |
| Mäurer, M | 1 |
| Wesemann, W | 1 |
| Becker, G | 1 |
| Tanaka, M | 1 |
| Sotomatsu, A | 1 |
| Kanai, H | 1 |
| Hirai, S | 1 |
| Asenjo, A | 1 |
| Rojas, G | 1 |
| Aranda, L | 1 |
| Weinstein, V | 1 |
| Oberhauser, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind, Randomised, Placebo-controlled Parallel Group Study to Investigate the Effect of EGCG Supplementation on Disease Progression of Patients With Multiple System Atrophy (MSA)[NCT02008721] | Phase 3 | 92 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for deferoxamine and Parkinson Disease
| Article | Year |
|---|---|
Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Biological Availability; Blood-Brain Barrier | 2021 |
Parkinson's disease and free radicals. Mechanism of neurodegeneration and neuroprotection.
Topics: Corpus Striatum; Deferoxamine; Free Radicals; Humans; Hydroxyl Radical; Nerve Degeneration; Neurons; | 1996 |
22 other studies available for deferoxamine and Parkinson Disease
| Article | Year |
|---|---|
Neuroprotective effects of a brain permeant 6-aminoquinoxaline derivative in cell culture conditions that model the loss of dopaminergic neurons in Parkinson disease.
Topics: Animals; Brain; Cell Culture Techniques; Cells, Cultured; Dopaminergic Neurons; Male; Mice, Inbred C | 2015 |
New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Dopaminergic Neurons; Female; Male; Mice, Inbred C | 2016 |
Adamantyl- and other polycyclic cage-based conjugates of desferrioxamine B (DFOB) for treating iron-mediated toxicity in cell models of Parkinson's disease.
Topics: Astrocytes; Cell Line; Cell Survival; Cells, Cultured; Deferoxamine; Humans; Iron; Iron Chelating Ag | 2017 |
Desferrioxamine Ameliorates Lipopolysaccharide-Induced Lipocalin-2 Upregulation via Autophagy Activation in Primary Astrocytes.
Topics: Animals; Astrocytes; Autophagy; Deferoxamine; Lipocalin-2; Lipopolysaccharides; Parkinson Disease; R | 2022 |
Deferoxamine and Curcumin Loaded Nanocarriers Protect Against Rotenone-Induced Neurotoxicity.
Topics: Antioxidants; Cell Line, Tumor; Curcumin; Deferoxamine; Humans; Iron Chelating Agents; Lipid Peroxid | 2020 |
Analogues of desferrioxamine B designed to attenuate iron-mediated neurodegeneration: synthesis, characterisation and activity in the MPTP-mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Ascorbic Acid; Benzothiazoles; | 2017 |
Targeted Brain Delivery of Rabies Virus Glycoprotein 29-Modified Deferoxamine-Loaded Nanoparticles Reverses Functional Deficits in Parkinsonian Mice.
Topics: Animals; Brain; Deferoxamine; Drug Delivery Systems; Glycoproteins; Male; Mice; Mice, Inbred C57BL; | 2018 |
Desferrioxamine and dextromethorphan combination exhibited synergistic effect and reversed the catalepsy behaviour in 6-hydroxydopamine hydroydopamine administered rats through regulating brain glutamate levels.
Topics: Animals; Antioxidants; Catalepsy; Corpus Striatum; Deferoxamine; Dextromethorphan; Disease Models, A | 2019 |
Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Topics: Administration, Intranasal; alpha-Synuclein; Animals; Antigens, CD; Antigens, Differentiation, Myelo | 2013 |
Ameliorating effects of combined curcumin and desferrioxamine on 6-OHDA-induced rat mode of Parkinson's disease.
Topics: Animals; Brain; Curcumin; Deferoxamine; Disease Models, Animal; Dopamine; Drug Interactions; Male; N | 2014 |
Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds.
Topics: Acetylcysteine; alpha-Synuclein; Antioxidants; Apigenin; Ascorbic Acid; Deferoxamine; Dose-Response | 2011 |
α-Synuclein expression is modulated at the translational level by iron.
Topics: alpha-Synuclein; Animals; Brain; Cells, Cultured; Deferoxamine; Ferric Compounds; HEK293 Cells; Huma | 2012 |
Effect of quercetin and desferrioxamine on 6-hydroxydopamine (6-OHDA) induced neurotoxicity in striatum of rats.
Topics: Animals; Behavior, Animal; Corpus Striatum; Deferoxamine; Disease Models, Animal; Dopamine; Drug The | 2013 |
Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease.
Topics: Adamantane; Animals; Astrocytes; Benzoates; Cells, Cultured; Deferasirox; Deferoxamine; Dopaminergic | 2013 |
1-Methyl-4-phenylpyridinium (MPP+)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide.
Topics: 1-Methyl-4-phenylpyridinium; Aconitate Hydratase; Animals; Antioxidants; Apoptosis; Caspase 3; Caspa | 2003 |
Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Brain; Brocresine; | 2004 |
Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cell Line; Coenzymes; Deferoxamine | 2006 |
Peripheral iron metabolism in patients with Parkinson's disease.
Topics: Aged; Circadian Rhythm; Deferoxamine; Female; Ferritins; Humans; Injections, Intramuscular; Iron; Ma | 1994 |
The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease.
Topics: Animals; Deferoxamine; Dominance, Cerebral; Ferritins; Free Radicals; Humans; Hydrogen Peroxide; Hyd | 1993 |
Iron accumulation in the substantia nigra in rats visualized by ultrasound.
Topics: Animals; Deferoxamine; Dose-Response Relationship, Drug; Ferritins; Humans; Iron; Oxidopamine; Parki | 1999 |
Dopa and dopamine cause cultured neuronal death in the presence of iron.
Topics: Adenosine Diphosphate; Animals; Antioxidants; Catalase; Cell Membrane; Cell Survival; Cells, Culture | 1991 |
[Cytosiderosis and deposits of iron in the ventrolateral nucleus of the thalamus in Parkinson's disease. Clinical and experimental study].
Topics: Animals; Cerebral Cortex; Cytoplasmic Granules; Deferoxamine; Electromyography; Ferritins; Haplorhin | 1969 |